RxDoctor Payments Data

John Shallcross, MD

Gastroenterology · Birmingham, ALNPI 1417937731

Payments from drug & device makers

$2,569in general payments, 2019–2025

Across 143 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$474
  • Pfizer$388
  • Johnson & Johnson$359
  • Bristol Myers Squibb$266
  • Acumed LLC$203
  • Takeda Pharmaceuticals U.S.A., Inc.$133
  • plus $748 from 20 others

What the payments were for

  • Consulting fees$151%
  • Food & beverage$2,55499%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,569 in reported general payments places this provider in the 35th percentile of 225 gastroenterology providers in Alabama.

See all gastroenterology providers in Alabama

Medicare billing

Part B allowed, 2024
$64,817
Medicare patients
190
Services billed
1,070

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C36$4,965
Budesonide DrBudesonide26$2,972
Colestipol Hcl31$2,753
Pantoprazole Sodium183$2,619
Famotidine103$2,545
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,755
Valganciclovir Hcl11$691
Omeprazole15$485
Dicyclomine Hcl13$426
Ondansetron Hcl15$389
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl20$264
Promethazine Hcl11$253
Metronidazole25$131
Ciprofloxacin Hcl13$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$85$4,96536 claims
Braintree Laboratories, Inc.Sutab$14$1,75511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 225 gastroenterology providers in Alabama.

Other gastroenterology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →